TG Therapeutics

is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.

Product Pipeline


Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.


TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.

For Investors

Stock Quote at: Oct 24, 4:00PM EDT

Last: $10.89

Change: $0.84 (8.36%)

Quotes provided by Google - Min 15 minute delay